2024 was a year of strategic delivery. Launch of Eroxon, an over the counter (OTC) erectile dysfunction (ED) gel, by its commercial partners in several new territories (including in the US by Haleon) enabled Futura Medical to post a maiden profit. At end-2024, Eroxon was sold in 15 countries across Europe, the Americas, and Middle East. To date, it has generated cumulative revenues of £17m for Futura. Management is working with partners to support future launches, aiming to have Eroxon available in at least 20 markets by end-2025, and implementing commercial learnings to target Eroxon more effectively to those men most likely to benefit. Progress also continues with range extension (Eroxon Intense) and new product (WSD4000) development.